Racial disparities in treatment use for multiple myeloma
Racial disparities in treatment use for multiple myeloma
复制标题
DOI：
10.1002/cncr.30526
复制
发表时间：
2017-05-01
期刊：
影响因子：
6.2
通讯作者：
Wildes, Tanya M.
中科院分区：
文献类型：
--
作者：
Fiala, Mark A.;Wildes, Tanya M.
背景最近的治疗进展极大地改善了多发性骨髓瘤患者的预后。然而，这些新的、更有效的治疗方法中的一些是密集的、更有效的，它们的使用率仍然很低，特别是在黑人患者中。方法在当前的研究中，作者利用监测、流行病学和最终结果(SEER)-Medicare链接数据库回顾了干细胞移植和Bortezomib的使用模式。结果在控制了总体健康和潜在的获得障碍后，黑人患者的比例为37%(P
BACKGROUNDRecent treatment advances have greatly improved the prognosis of patients with multiple myeloma. However, some of these newer, more effective treatments are intensive and expensive and their use remains low, particularly among black patients.METHODSIn the current study, the authors reviewed the use patterns of stem cell transplantation and bortezomib using the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database.RESULTSAfter controlling for overall health and potential access barriers, black patients were found to be 37% (P